We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(Wall Street Journal Health Blog) May 11, 2010 - It’s been nearly three and a half years since Pfizer abruptly pulled the plug on its $800 million effort to develop torcetrapib after the HDL-cholesterol raising drug was linked to a higher risk of death in a 15,000-patient study.
(The Seattle Times) May 11, 2010 - William James, president of the American Academy of Dermatology Association, said statistics show skin cancer now afflicts more Americans than all other cancers combined.
(Reuters) May 12, 2010 - Regeneron Pharmaceuticals Inc, a relatively unknown biotechnology company based in sleepy Tarrytown, New York, is not exactly a household name. But that is likely to change fast.
(ABCNews) May 12, 2010 - "Good Morning America" anchor Sam Champion this morning had surgery to remove skin cancer cells from his shoulder, undergoing the procedure on live television.
(Los Angeles Times Booster Shots) May 11, 2010 - The Canadian physician whose research escalated safety concerns about the Type 2 diabetes drug rosiglitazone (marketed as Avandia) is urging the U.S. Food and Drug Administrationto call a halt to a major international trial designed to compare the safety of Avandia against another diabetes drug in the same class.
(Sanford-Burnham) May 11, 2010 - Researchers deliver a better understanding of anti-cell death proteins and a potential antagonist to defeat them.
(MorningStar) May 11, 2010 - The Food and Drug Administration plans to take a look at a new genetic test that Walgreen Co. plans to start selling at 6,000 of its stores this month.
(Yahoo! Finance) May 12, 2010 - Soligenix, Inc., a late-stage biopharmaceutical company, announced today that patient enrollment has been completed in a randomized, double-blind, placebo-controlled Phase 2 clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens.
(FOX Business) May 11, 2010 - Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients.
(ScienceBlog) May 11, 2010 - Among African Americans, colorectal cancer is the third most common cause of cancer-related death.